GlassScriptPhysician profile
Sherman Dunn
NPI 1730109281
$4,665.20
in general payments reported to CMS, 2019-2025
26 companies · $722 in 2025
The $722 reported for 2025 was more than what 87% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,019 · 2020: $125 · 2021: $648 · 2022: $511 · 2023: $480 · 2024: $1,160 · 2025: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,361.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $691.17 | 2019-2021 | |
| Glaxosmithkline, LLC. | $499.72 | 2022-2024 | Arexvy |
| Astellas Pharma US INC | $490.91 | 2023-2025 | Veozah |
| Baxter Healthcare | $268.72 | 2020-2024 | Starling System |
| Myovant Sciences INC. | $250.01 | 2021-2022 | |
| Agile Therapeutics, INC. | $249.66 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $229.36 | 2019 | |
| Csl Behring | $185.24 | 2023-2025 | Kcentra |
| Hologic Sales and Service, LLC | $141.33 | 2024 | Acessa Provu System, Omni Hysteroscope, Novasure |
| Organon LLC | $136.19 | 2025 | Jada System |
| Abbott Laboratories | $132.62 | 2022 | |
| Exeltis, USA INC. | $127.84 | 2025 | Twirla, Slynd |
| Axsome Therapeutics, INC. | $125.00 | 2025 | Auvelity |
| Novo Nordisk INC | $125.00 | 2024 | Wegovy |
| Mayne Pharma Commercial LLC | $125.00 | 2025 | Annovera |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $124.73 | 2024 | Epclusa |
| Evofem Biosciences, INC. | $123.56 | 2021 | |
| Roche Diagnostics Corporation | $117.40 | 2019 | |
| Shield Therapeutics INC | $111.06 | 2024 | |
| Lupin INC. | $106.01 | 2019 | |
| Ge Healthcare | $104.19 | 2022 | |
| Channel Medsystems, INC. | $76.39 | 2023 | |
| Merck Sharp & Dohme LLC | $44.23 | 2022-2024 | Bridion |
| Ethicon US, LLC | $36.21 | 2025 | Dermabond, Stratafix |
| Medtronic, INC. | $25.00 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $18.65 | 2024 | Exparel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherman Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.